2016 OptumRx Trend Insights

Size: px
Start display at page:

Download "2016 OptumRx Trend Insights"

Transcription

1 2016 OptumRx Trend Insights

2 TREND SUMMARY Overall trend summary This report offers our perspective of the forces driving trend and spending for 2015 vs We define trend as growth in year-over-year spending for our overall book-of-business. The headline net trend figure of 2.8% is the combined average for both traditional and specialty drugs, net of any rebates. Inflation was the biggest trend driver for both drug classes, with a net impact of 6.0%. Aggregate utilization increased slightly (less than 1%), but OptumRx trend management efforts contributed to an overall reduction of 4.1%. 2.8% OVERALL TREND 0.9% TRADITIONAL TREND 13.2% SPECIALTY TREND We know that our clients want to know specifically about themselves: What s driving my trend and what can I do about it? We always look forward to having those one-to-one conversations. But our clients also want to understand how they compare. Where do they stand against our book-of-business, as well as against different markets? These benchmark results can help identify best-in-class strategies and solutions. Note: The trend statistics shown in this report are true aggregate numbers. They are not dependent on having a predetermined group of management strategies in place. Scope This analysis is based on our carve-out commercial, and carve-in ASO commercial book-of-business. This article reflects claims experience for the period between January-November 2015 vs. January-November Overall trend (2.8%) is based on post-rebate data. All other metrics reflect pre-rebate figures. OptumRx 2016 Trend Insights 1

3 TREND SUMMARY What is happening in the industry at large? In order to place the OptumRx experience in context, let s begin by reviewing some industry-level figures. OptumRx participated in a recent survey of managed care organizations, health insurers, pharmacy benefit managers (PBMs) and third party administrators nearly 100 benefits payers in all. 1 For employer groups nationwide: Prescription drug costs continue to increase at double-digit rates, well in excess of costs for medical plans. 1 OptumRx 2016 main trend drivers Combined (traditional and specialty) prescription drug costs rose 11.3% in 2016 for active employees and retirees under age Specialty drug/biotech medications increased at a much higher rate, 18.9%. 1 OptumRx-specific results 6% 4.1% Increased reference prices (inflation) OptumRx trend management While OptumRx participated in the survey, OptumRx clients, on average*, saw much better results: Combined (traditional and specialty) prescription drug costs: 2.8% Stand-alone traditional drugs: 0.9% Specialty trend: 13.2% Trend management results: 4.1% OptumRx trend management activities are critical to helping our clients achieve their benefit goals. Of course, strategies will vary, since each plan sponsor has a unique set of goals and cost drivers. Turn to pages for a summary of our trend strategies. Our clients employ a variety of active programs and strategies to improve care and reduce costs. Our programs help manage specialty medications, drive generic and preferred brand utilization and manage the supply chain for ingredient cost savings through improved pricing. Clients can also take advantage of price protection, rebate contracts, and customized plan design advice. *These are average results and are not guaranteed. Client experience will vary depending on plan design, utilization, demographics and other variables. OptumRx 2016 Trend Insights 2

4 SPECIALTY TREND Specialty trend As they have for the past several years, specialty medications continue to be the principal driver of overall gross trend. These high-cost drugs account for 34.4% of the pharmacy spend, up from 31.8% in Specifically, specialty drug costs can be attributed to three main drivers: 13.2% SPECIALTY TREND 10.0% inflation The most significant driver, led by considerable price increases for chronic inflammatory, multiple sclerosis, and HIV medications. Specialty drugs account for 35% of all prescription drug spending. 1 But less than 1% of all medications are specialty drugs % utilization Increased moderately for specialty medications. 1.7% drug mix A mitigating factor as less costly drugs were utilized, due partially to the decrease in use and expenditures for hepatitis C medications, as well as increased use of HIV medications, which cost much less than most specialty drugs. OptumRx 2016 Trend Insights 3

5 SPECIALTY TREND Top 5 specialty classes by expenditure and trend Inflation was the most significant driver for specialty medications, led by chronic inflammatory, multiple sclerosis, and HIV. Utilization increased moderately: a 4.9% increase. Shifting the drug mix to less costly drugs helped, especially for hepatitis C and HIV medications. Mixed results show increases and decreases: Specialty medications are responsible for 88% of overall gross trend +33.2% trend +7.9% trend +20.1% trend 1 Chronic Inflammatory 2 Multiple Sclerosis 3 Oncology (cancer) +20.2% trend 32.4% trend 4 HIV 5 Hepatitis C OptumRx 2016 Trend Insights 4

6 SPECIALTY TREND Chronic inflammatory summary 88% claims 91% costs Over 2015, the proportion grew by 8.1% of overall pharmacy spending represented by specialty medications 33.2% total specialty trend There are many inflammatory conditions, including rheumatoid arthritis, plaque psoriasis, ulcerative colitis, and Crohn s disease. This helps to explain the overall cost as a class. In addition, high inflation and increased utilization pushed chronic inflammatory conditions to the top in overall spending, 29.5%, plus the highest PMPM increase of any class. Some of the most-used drugs in the class are high-cost biologics: Humira and Enbrel. Recent hopes for cheaper biosimilar competitors have dimmed. While a biosimilar to Humira has won FDA approval, it may not be marketed until 2018, due to costly patent litigation. Read more here. Oncology (cancer) summary 20.1% total specialty trend The oncology class includes hundreds of different cancer types. Together, these ranked as the 3rd highest spending category at 13.1% and saw the 2nd highest PMPM increase. Primarily, these increases were driven by expensive new therapies. Seven of the top 10 drugs by market share averaged over $7,000 per claim. Ibrance ($9,000 per prescription), more than doubled its utilization. Imbruvica ($10,000 per prescription) also had a significant increase in utilization. Read more about Ibrance here. In January 2017, Imbruvica received an expanded FDA approval to treat patients with marginal zone lymphoma, which will drive usage even higher. OptumRx 2016 Trend Insights 5

7 SPECIALTY TREND HIV summary +102% trend Fast growth for Cystic Fibrosis 20.2% total specialty trend The HIV class saw the 4th highest spend, 12.8%, and the 4th highest PMPM increase. This was caused by increased use of newer combination therapy medications, which are more expensive than older products. This is not necessarily a bad thing. Best-practice HIV therapy relies on multiple antivirals to slow the virus progression. So drug manufacturers now combine two, three, and even four agents in one tablet or capsule. The combined drugs are more effective and patients tend to be more adherent when there are fewer pills to take. Most HIV patients take three or more antiviral medications. 42% of OptumRx members take one unit versions: 1/3 of those contain four drugs, and 2/3 contain three drugs. While not the biggest category in dollar terms, cystic fibrosis had the 2nd highest trend over this period: 102.1%. This also led to the 5th highest PMPM increase. This stems from Orkambi, a breakthrough treatment for the underlying cause of cystic fibrosis (not just symptoms). Priced at $16-18,000/ prescription, a 300% increase in utilization over the reporting period yields tremendous growth. Read more about Orkambi here. Hepatitis C summary 32.4% total specialty trend The most notable change in this class is the slowing number of people being treated. Nationwide, HCV treatments have gone from 20-30,000 per year in earlier periods, up to 170,000 patients in That peaked at nearly 250,000 patients in 2015, but already the number of new patients was beginning to fall as the year progressed. 2 That decrease has continued, as we continue to reduce the initial group of patients with the highest need. 2 For this reporting period, fewer patients generated 1/3 fewer claims. Harvoni use dropped 42%, from over 10,000 claims to about 5,700. Sovaldi and Olysio saw a notable decrease as well. In all, HCV has dropped from 3rd to 5th in specialty class spending. It has also gone from being the 2nd highest contributor to class trend to actually reducing trend. OptumRx 2016 Trend Insights 6

8 TRADITIONAL TREND Traditional trend Traditional medications played a much smaller role in spending growth, accounting for just 12% of overall gross trend. Nevertheless, traditional medications still make up most of the pharmacy dollar over 65%. Looking at the three typical drivers, utilization was nearly flat (0.8%) while inflation and drug mix essentially cancelled each other out: 0.9% TRADITIONAL TREND Utilization was nearly flat, while inflation and drug mix cancelled each other out. 42% inflation Led by large price increases for insulin, and anaphylaxis therapy (i.e. Epi-Pen ). These were supplemented by more moderate increases for several classes, including erectile dysfunction agents and inhaled asthma combinations, plus several types of diabetes drugs (the biguanides, some non-insulin injectables, and DPP-4 inhibitors). 1.7% drug mix Helped mitigate the increases by substituting less costly drugs, mainly generics. Some generics, such as atypical antipsychotics and antidepressants, saw significant price improvements. In addition, we continued our vigilance over the use of compounded drugs, which can be quite costly. (The average cost for a compound prescription in 2015 was over $1,000). We noticed that the majority of the inflationary increases occurred in the earlier months of the comparison period. Since then we have actually seen slowing inflation, a trend we expect to continue. OptumRx 2016 Trend Insights 7

9 TRADITIONAL TREND Trend increase drivers The trend for injectable diabetic medications, SGLT-2 inhibitors, ADHD and narcolepsy medications was driven by both increased utilization and inflation. Insulin continues to have dramatic AWP increases, but also slight utilization increases. Oral anticoagulant trend was driven by increased utilization of more costly options (e.g. Eliquis and Xarelto ). On a more favorable note, ADHD saw a 2% increase in generic utilization, which helped to slightly mitigate its trend. Class Insulin Injectable Diabetic SGLT-2 Inhibitors and Combos Oral Anticoagulants ADHD and Narcolepsy Trend 9.1% 40.1% 44.3% 33.4% 5.8% Trend decrease drivers Atypical antipsycotics and NSAIDs saw reduced cost and drug mix due to generics for Abilify and Celebrex, respectively. Opioids had both decreased utilization and drug mix, while statins were driven by the new release of generic Crestor. Class Compounds Atypical Antipsycotics Statins NSAIDs Opioids Trend 95.2% 19.2% 10.7% 22.1% 9.8% OptumRx 2016 Trend Insights 8

10 TRADITIONAL TREND Top traditional classes by expenditures Class 2015 % 2016 % Trend Insulin 8.2% 8.9% 9.1% ADHD and Narcolepsy Medications 5.6% 5.9% 5.8% Statins and Combos 4.5% 4.0% 10.7% Antidepressants 4.0% 3.9% 2.0% Inhaled Asthma/COPD Combo 2.9% 3.2% 10.9% The top 10 traditional classes account for approx. 40% of expenditures Anticonvulsants 2nd Generation 2.9% 3.1% 8.5% Opioid Agonists and Combos 3.2% 2.8% 9.8% Contraceptives 2.7% 2.8% 4.3% The affect on traditional expenditures The top 10 traditional classes affect traditional expenditures in different ways: Diabetes: Insulin and SGLT inhibitors increased utilization and inflation ADHD and Narcolepsy: Increased utilization and inflation offset by higher generic use Statins: Increased generic use with Crestor going off-patent Antidepressants: Improved pricing for generics (especially Cymbalta ) Asthma/COPD: Major drugs are brands, so expect AWP inflation. Most significant is Advair Anticonvulsants: AWP inflation for Lyrica, but also increased utilization Opioids: Increased use of generics (OxyContin ) as well as decreased use of Subsys ($12-16,000/ Rx) Contraceptives: Inflation, increased utilization, offset by improved drug mix DPP-4: Januvia /Janumet patent expiration, but also high inflation Atypical Antipsychotics: Price improvement for generic Abilify (31% decrease) OptumRx 2016 Trend Insights 9

11 CROSS CLASS UTILIZATION Top impact drugs Traditional and specialty drugs with trend increases/decreases: Drug Name Percent PMPM Change Contribution to Trend Orkambi 292.8% 5.6% Trend causes Triumeq Humira Pen 153.8% 43.6% 5.4% 29.1% Increase: Novel agent (i.e. Orkambi) Greater MD acceptance (i.e. Triumeq) Decrease: Patent expired (i.e. Abilify, Glumetza, Crestor) Reduced utilization (i.e. Harvoni) High inflation and utilization (i.e. Humira pen) New indication; increased dosage (i.e. Stelara) Truvada Stelara Abilify Glumetza Harvoni Crestor -84.7% -67.9% -43.4% -24.8% Decrease 37.8% 27.9% Increase 5.6% 5.1% -14.0% -5.8% -32.4% This chart shows some of the biggest movers by percentage of trend increase or decrease. There is no common theme or cause that unites all of them. For example, the HCV drug, Harvoni experienced slowing utilization due to the general fall-off in HCV treatments. -8.8% Meanwhile, Orkambi saw explosive growth as a novel agent that for the first time can treat the underlying protein deficiency in cystic fibrosis (see page 9). An existing drug, Stelara, received a new indication for Crohn s disease in 2016, which helped drive new sales. OptumRx 2016 Trend Insights 10

12 CROSS CLASS UTILIZATION Many treatments require traditional and specialty drugs Oftentimes we look at pharmacy spend in distinct groupings, separately isolating the evaluation of specialty and traditional medications. However, members are obtaining treatments for specific conditions from both specialty and traditional medications. Cancer treatment has the greatest reach across specialty and traditional, with traditional medications accounting for 88% of the claims, and specialty medications accounting for 91% of the cost. Oncology reaches across traditional and specialty Traditional and specialty drug use by class* Cost Claims Traditional Specialty Traditional Specialty 88% claims 91% costs Oncology Asthma/COPD Antibiotics 9% 96% 94% 91% 4% 6% 88% >99% >99% 12% <1% <1% Seizure 96% 4% >99% <1% Cholesterol 98% 2% >99% <1% 88% of all oncology claims are traditional 91% of all oncology costs are specialty *Percentages rounded for clarity. Rows may not equal 100%. OptumRx 2016 Trend Insights 11

13 TREND MANAGEMENT OptumRx trend management The OptumRx approach to managing trend is to focus on connecting total condition spend and pharmacy s impact across benefits. We make the connections between clinical efficiency, cost savings and consumer choice that help payers manage the total cost of the condition across benefits and help consumers more easily navigate the system. Clinical efficiency Cost savings Consumer choice OptumRx strategies and savings Premium Formulary 1-3% decrease in Rx spend Retrospective Drug Utilization Review (Safety Management) $138 Rx savings Utilization Management % decrease in Rx spend (Gaps in Care) $547 medical savings Specialty Management 9-14% decrease in specialty Rx spend Vigilant Drug List ~0.5% decrease in net PMPM spend Compound Management Strategy 90% reduction in compound expenditures OptumRx 2016 Trend Insights 12

14 TREND MANAGEMENT Pharmacy care services: The next generation $11-16 PMPM savings on medical costs, incremental to pharmacy savings 3 The pharmacy model has to change. OptumRx is taking concrete action to evolve pharmacy services to emphasize value over just price and volume. We re aligning with physicians, including our own growing health network, to deliver better and more efficient care. We re shifting the scorecard from drug pricing to net promoter score, satisfaction, medical costs and care outcomes. That s a new agenda that will serve everyone s interests. Old Approach OptumRx: Value over volume Channel flexibility 12% increase in adherence on average for targeted populations 4 Mail-driven model Retail-driven model Empowering physicians Tailored offerings Aligned with client goals to lower total health care costs Site of care strategies Synchronized engagement 60% enrollment in condition management programs through pharmacy 5 Aligning with client interests to drive value We re taking a big-picture, lowest net cost approach that adds value to the health system and aligns with client goals: Channel flexibility means promoting member choice and convenience over PBM profit. Synchronized engagement turns Rx member calls health care s most frequent touchpoint into opportunities to engage individuals with health and savings options. Determining the site of care best suited to optimal health and financial results. Partnering with clients to tailor customized benefit plan solutions that drive best outcomes. We empower physicians with real-time, patient-specific information through Electronic Medical Records to avoid incomplete data and missed clinical opportunities. OptumRx 2016 Trend Insights 13

15 References 1. Segal Consulting Segal Health Plan Cost Trend Survey. PDF. 2. IMS Institute. Medicines Use and Spending in the U.S. April PDF. 3. Optum Study of 80+ Clients, OptumRx Book of Business, OptumRx Client Data, January-October About OptumRx OptumRx specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. Our high-quality, integrated services deliver optimal member outcomes, superior savings and outstanding customer service. We are an Optum company a leading provider of integrated health services. To learn more about OptumRx and to discuss potential pharmacy benefit savings, please us at or visit optum.com/optumrx Main Street, Irvine, CA optum.com/optumrx All Optum trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners Optum, Inc. All rights reserved.

San Francisco Health Service System

San Francisco Health Service System San Francisco Health Service System Pharmacy Trends Board Forum: November 10, 2016 Prepared by: Aon s Pharmacy Point of View We Believe Getting patients to the RIGHT drug at the RIGHT channel for the RIGHT

More information

Put Money Back in Your Classroom Finding the hidden revenue in your pharmacy benefits

Put Money Back in Your Classroom Finding the hidden revenue in your pharmacy benefits Put Money Back in Your Classroom Finding the hidden revenue in your pharmacy benefits Presented by Howard Mazzafro, Vice President Innovative Slide 1 of 25 Solutions. Enduring Principles. Innovative Solutions.

More information

Specialty Drug Spending

Specialty Drug Spending Specialty Drug Spending The IMS Institute for Healthcare Informatics reported that spending on specialty pharmaceuticals almost doubled from 2010 to 2015, and spending on this subset of drugs was responsible

More information

Understanding Biosimilars and Projecting the Cost Savings to Employers Update

Understanding Biosimilars and Projecting the Cost Savings to Employers Update Understanding Biosimilars and Projecting the Cost Savings to Employers Update Prepared by: Milliman, Inc. Frank Kopenski Jr, ASA, MAAA Principal and Consulting Actuary Katie Holcomb, FSA, MAAA Actuary

More information

Transparency Debate in PBM Industry Consumer Driven Healthcare Summit Sept , 2006 in Washington, DC. Marina Tackitt PBMI

Transparency Debate in PBM Industry Consumer Driven Healthcare Summit Sept , 2006 in Washington, DC. Marina Tackitt PBMI Transparency Debate in PBM Industry Consumer Driven Healthcare Summit Sept. 13-15, 2006 in Washington, DC Marina Tackitt PBMI Session Objectives Summarize Complexity of Drug Benefit Management Define Concept

More information

The Pharma/Payer Relationship Strategies for the Next Two Years

The Pharma/Payer Relationship Strategies for the Next Two Years Health & Life Sciences The Pharma/Payer Relationship Strategies for the Next Two Years by Mark Mozeson Nipon Das, M.D. The power to determine what pharmaceutical products are bought and at what price has

More information

Understanding the Prescription Drug Landscape & Best Practices for Managing the Benefit

Understanding the Prescription Drug Landscape & Best Practices for Managing the Benefit Understanding the Prescription Drug Landscape & Best Practices for Managing the Benefit Diane Clausen Pharmacy Benefit Consultant Pharmaceutical Strategies Group, LLC 5360 Legacy Drive Building 3, Suite

More information

Transitioning to Express Scripts

Transitioning to Express Scripts Transitioning to Express Scripts Welcome to Express Scripts. We re pleased to announce that, beginning January 1, 2017 the Michigan Tech prescription benefit will be managed by Express Scripts. Express

More information

Control Costs and Increase Employee Engagement With Consumer Advantage

Control Costs and Increase Employee Engagement With Consumer Advantage Control Costs and Increase Employee Engagement With Consumer Advantage Engage Employees Faced with rising healthcare costs, employers are turning to consumer-driven strategies to provide more cost-efficient

More information

Your Prescription Drug [ or 20%] Plan with Refill By Mail

Your Prescription Drug [ or 20%] Plan with Refill By Mail Refill By Mail The Home Delivery Pharmacy sends drugs you take on a regular basis right to your door. And you get a larger supply of medicine for less money. 1 Your Prescription Drug [15-40-75 or 20%]

More information

Drafting Pharmacy Benefit Manager Contracts: Controlling Costs, Avoiding Hidden Fees

Drafting Pharmacy Benefit Manager Contracts: Controlling Costs, Avoiding Hidden Fees Presenting a live 60-minute webinar with interactive Q&A Drafting Pharmacy Benefit Manager Contracts: Controlling Costs, Avoiding Hidden Fees Navigating Prescription Drug Pricing Complexities, Selecting

More information

An Economic Analysis of Generic Drug Usage in the U.S.

An Economic Analysis of Generic Drug Usage in the U.S. September 2011 $931 Billion SAVINGS An Economic Analysis of Generic Drug Usage in the U.S. EXECUTIVE SUMMARY As government leaders in Washington and across the country look for ways to cut health care

More information

YASHAJIT SAHA & ABHISHEK SHARMA, SUBJECT MATTER EXPERTS, RESEARCH & ANALYTICS ADVANCED ANALYTICS: A REMEDY FOR COMMERCIAL SUCCESS IN PHARMA.

YASHAJIT SAHA & ABHISHEK SHARMA, SUBJECT MATTER EXPERTS, RESEARCH & ANALYTICS ADVANCED ANALYTICS: A REMEDY FOR COMMERCIAL SUCCESS IN PHARMA. YASHAJIT SAHA & ABHISHEK SHARMA, SUBJECT MATTER EXPERTS, RESEARCH & ANALYTICS ADVANCED ANALYTICS: A REMEDY FOR COMMERCIAL SUCCESS IN PHARMA wns wns ADVANCED ANALYTICS: A REMEDY FOR COMMERCIAL SUCCESS IN

More information

The transition to OptumRx is designed to help us better serve your employees and help improve their overall experience:

The transition to OptumRx is designed to help us better serve your employees and help improve their overall experience: September 27, 2013 RE: Pharmacy Benefit Transition Plan for Oxford Clients Dear Valued Oxford Client, We are pleased to confirm that, effective Oct. 1, 2013, your pharmacy benefit services are being administered

More information

2009 National Pharmacy Study SM

2009 National Pharmacy Study SM Mass Merchandiser Performance September 2009 Healthcare Practice Table of Contents Topic Page # Overview of Findings... MM-3 Overall Customer Satisfaction...MM-5 Non-Pharmacist Staff MM-8 Store Convenience

More information

Perspectives Spring The Drug Pipeline: What s in it and why it matters.

Perspectives Spring The Drug Pipeline: What s in it and why it matters. Perspectives Spring 2016 The Drug Pipeline: What s in it and why it matters. 2 The Drug Pipeline: What s in it and why it matters. Author: Mark Jackson, BScPhm, BComm, RPh Consultant Pharmacist, TELUS

More information

Medicare Advantage risk adjustment: How deep is the well?

Medicare Advantage risk adjustment: How deep is the well? Medicare Advantage risk adjustment: How deep is the well? With increasing regulation and focus on quality, comprehensive risk and quality programs are more important than ever. Whether you re engaging

More information

COMMUNITY OUTREACH STRATEGIES

COMMUNITY OUTREACH STRATEGIES COMMUNITY OUTREACH STRATEGIES Program Overview & Strategies Table of Contents Program Overview & Strategies... 2,3 Best Practices... 4 Promotional Materials... 5 Sample Promotional Materials... 6,7 Frequently

More information

WINNING BRAND VS. GENERIC COMPETITION

WINNING BRAND VS. GENERIC COMPETITION WINNING BRAND VS. GENERIC COMPETITION - Competition 2.0: Brands vs. Generics - Winning Beyond the Molecule www.bernardassociatesllc.com Innovator and generic companies are colliding as they invade each

More information

Media Kit A L L I A N C E H E A L T H

Media Kit A L L I A N C E H E A L T H Media Kit A L L I A N C E H E A LT H Our Philosophy Empowering Consumers Through Social Health Communities Alliance Health is an innovative technology company setting the standard for consumer-centric

More information

Over a Hundred Reporting Clients throughout the country. 95%+ Client Retention

Over a Hundred Reporting Clients throughout the country. 95%+ Client Retention The Leader in Web-based Reporting for Managed Care Organizations Diverse base of Managed Care clients (IPAs, PHOs, HMOs & MSOs) Providing Managed Care Analytics and Business Intelligence for over 10 years

More information

Medical Pharmacy Trend Report: Managing the Trends and Complexity of Provider- Administered Drugs

Medical Pharmacy Trend Report: Managing the Trends and Complexity of Provider- Administered Drugs Medical Pharmacy Trend Report: Managing the Trends and Complexity of Provider- Administered Drugs Thursday, March 10, 2016 1:00 2:30 EST 12:00 1:30 CST 11:00 12:30 MST 10:00 11:30 PST Casandra Stockman,

More information

REFERENCE CODE GDHC1180DFR PUBLICATION DATE M AY 2013

REFERENCE CODE GDHC1180DFR PUBLICATION DATE M AY 2013 REFERENCE CODE GDHC1180DFR PUBLICATION DATE M AY 2013 STELARA (PSORIASIS) - Executive Summary Table below presents key metrics for Stelara in the seven of the nine major pharmaceutical markets. Stelara:

More information

Maximizing Market Access: THE 5 MOST CRITICAL QUESTIONS TO ASK WHEN LAUNCHING A SPECIALTY DRUGS

Maximizing Market Access: THE 5 MOST CRITICAL QUESTIONS TO ASK WHEN LAUNCHING A SPECIALTY DRUGS Maximizing Market Access: THE 5 MOST CRITICAL QUESTIONS TO ASK WHEN LAUNCHING A SPECIALTY DRUGS by Jan Nielsen, division president, Access & Patient Support Are You Asking the Right Questions? We ve all

More information

Managing Risk and Uncertainty Through the Drug Life cycle. Recent FDA Initiatives. Theresa Mullin, PhD

Managing Risk and Uncertainty Through the Drug Life cycle. Recent FDA Initiatives. Theresa Mullin, PhD Managing Risk and Uncertainty Through the Drug Life cycle Recent FDA Initiatives Theresa Mullin, PhD Director Office of Strategic Programs US FDA Center for Drug Evaluation and Research October 14, 2014

More information

Coding Systems Understanding NDC and HCPCS

Coding Systems Understanding NDC and HCPCS Coding Systems Understanding NDC and HCPCS National Drug Code The National Drug Code (NDC) serves as a universal product identifier for prescription medications approved for human consumption. According

More information

Summary of Medicines Plan

Summary of Medicines Plan Summary of Medicines Plan Ministry of Public Health, Welfare and Sport Summary of Medicines Plan 1 Content Introduction 4 1 Accessibility of innovative medicines 5 Go to action 2 Tackle the high price

More information

Using Your Prescription. Drug Program. Answers to important questions about retail pharmacy and mail order purchasing

Using Your Prescription. Drug Program. Answers to important questions about retail pharmacy and mail order purchasing Using Your Prescription Drug Program Answers to important questions about retail pharmacy and mail order purchasing Welcome! We know you re going to enjoy the many advantages of your prescription drug

More information

The U.S. Wholesaler Market: Past, Present and Future

The U.S. Wholesaler Market: Past, Present and Future The U.S. Wholesaler Market: Past, Present and Future 2012 H. D. Smith National Sales & Management Conference August 8, 2012 John M. Gray President and CEO HDMA The History of HDMA 1876 2012 Exchange Hall,

More information

GREAT STRIDES IN SCIENCE WHAT ABOUT ACCESS? Marlene E. Haffner, MD, MPH 2nd IRDiRC Conference Shenzhen, China November 8, 2014

GREAT STRIDES IN SCIENCE WHAT ABOUT ACCESS? Marlene E. Haffner, MD, MPH 2nd IRDiRC Conference Shenzhen, China November 8, 2014 GREAT STRIDES IN SCIENCE WHAT ABOUT ACCESS? Marlene E. Haffner, MD, MPH 2nd IRDiRC Conference Shenzhen, China November 8, 2014 1982 WHAT HAS HAPPENED SINCE IN TECHNOLOGY ASSESSMENT AND. US Orphan Drug

More information

CRO partner in Rx/CDx Co-Development

CRO partner in Rx/CDx Co-Development CRO partner in Rx/CDx Co-Development DEDICATED DIALOGUE A sponsored roundtable discussion published in Pharmaceutical Executive Two Covance executives discuss a CRO s role in supporting Companion Diagnostics

More information

Drug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research

Drug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research Drug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research Drug Development Process by which new chemical entities

More information

Opportunities in the Health Care Practice at Analysis Group

Opportunities in the Health Care Practice at Analysis Group Opportunities in the Health Care Practice at Analysis Group Johns Hopkins Blomberg School of Public Health October 3, 2016 You Will Learn Today: Who the Analysis Group is What our Health Care Practice

More information

Research Brief. Findings From HSC NO. 22, APRIL Limited Options to Manage Specialty Drug Spending

Research Brief. Findings From HSC NO. 22, APRIL Limited Options to Manage Specialty Drug Spending Research Brief Findings From HSC NO. 22, APRIL 2012 Limited Options to Manage Specialty Drug Spending BY HA T. TU AND DIVYA R. SAMUEL Spending on specialty drugs typically high-cost biologic medications

More information

Moving from volume to value in the generic business model

Moving from volume to value in the generic business model Moving from volume to value in the generic business model CPhI Pre-connect conference Frankfurt 23rd October 2017 Copyright 2016 QuintilesIMS. All rights reserved. Key drivers to 2021 Global growth moderating

More information

Health Reform for New Health Reform Reporters Kaiser Family Foundation July 7, 2016

Health Reform for New Health Reform Reporters Kaiser Family Foundation July 7, 2016 Transcript provided by the (Tip: Click on the binocular icon to search this document) Health Reform for New Health Reform Reporters July 7, 206 The makes every effort to ensure the accuracy of written

More information

BIOLOGIC MEDICATIONS IN THE TREATMENT OF IBD. crohnsandcolitis.ca

BIOLOGIC MEDICATIONS IN THE TREATMENT OF IBD. crohnsandcolitis.ca BIOLOGIC MEDICATIONS IN THE TREATMENT OF IBD crohnsandcolitis.ca BIOLOGIC MEDICATIONS IN THE TREATMENT OF IBD INFLAMMATION AND IMMUNITY IN CROHN S AND COLITIS Inflammation is the body s normal and natural

More information

VALUE-BASED HEALTHCARE A MANUFACTURER S PERSPECTIVE PETER JUHN, MD, MPH VICE PRESIDENT AND GLOBAL HEAD, VALUE-BASED PARTNERSHIPS

VALUE-BASED HEALTHCARE A MANUFACTURER S PERSPECTIVE PETER JUHN, MD, MPH VICE PRESIDENT AND GLOBAL HEAD, VALUE-BASED PARTNERSHIPS VALUE-BASED HEALTHCARE A MANUFACTURER S PERSPECTIVE PETER JUHN, MD, MPH VICE PRESIDENT AND GLOBAL HEAD, VALUE-BASED PARTNERSHIPS NATIONAL CONFERENCE OF STATE LEGISLATURES SAN DIEGO, CA DECEMBER 10, 2017

More information

The Challenge of Pricing Combination Therapies

The Challenge of Pricing Combination Therapies The Challenge of Pricing Combination Therapies By David Greber and Srikant Vaidyanathan The role of combination therapies in medicine continues to grow. For the treatment of HIV/AIDS, cancer, and hepatitis

More information

Shifting Pharma Sales Models. Text for a pull out can go heretext for a pull out can go heretext for a pull out can go

Shifting Pharma Sales Models. Text for a pull out can go heretext for a pull out can go heretext for a pull out can go Text for a pull out can go heretext for a pull out can go heretext for a pull out can go Text for a pull out can go here Text for a pull out can go here Shifting Pharma Sales Models to Focus on Providing

More information

DR NEIL FISHER. Helicon Medical Writing Ltd, Director

DR NEIL FISHER. Helicon Medical Writing Ltd, Director PROFILE I am an experienced writer, skilled in writing and editing a wide range of medical communications and healthcare education documents for a variety of audiences. Integral to this is my command of

More information

Access Based Network Design A new approach to significantly reducing prescription drug benefit costs.

Access Based Network Design A new approach to significantly reducing prescription drug benefit costs. Payers and their benefit consultants and PBMs are continually seeking ways to bend the cost curve on prescription drug spending. There has been some success in this area as plan and formulary designs have

More information

DIGITAL EDITION BONUS CONTENT

DIGITAL EDITION BONUS CONTENT DIGITAL EDITION BONUS CONTENT Denise Myshko Forecasting Pharma s Future Given the volatility of today s financial landscape, c ompanies, more than ever, need a robust forecasting strategy that is clear,

More information

McKinsey Center for Government What's Driving the Recent Surge in New Drug Approvals?

McKinsey Center for Government What's Driving the Recent Surge in New Drug Approvals? McKinsey Center for Government What's Driving the Recent Surge in New Drug Approvals? Alexia Cesar, Philip Ma, Navjot Singh, Jeff Smith What's Driving the Recent Surge in New Drug Approvals? In 2012, the

More information

Overview. A brief from

Overview. A brief from A brief from Dec 2017 Getty Images What Are Compounded Drugs, and How Can They Be Kept Safe? Drug Quality and Security Act plays key role in important but potentially high-risk aspect of health care Overview

More information

Research Article Clinical Trial Risk in Hepatitis C: Endpoint Selection and Drug Action

Research Article Clinical Trial Risk in Hepatitis C: Endpoint Selection and Drug Action Canadian Gastroenterology and Hepatology Volume 216, Article ID 626271, 7 pages http://dx.doi.org/1.1155/216/626271 Research Article Clinical Trial Risk in Hepatitis C: Endpoint Selection and Drug Action

More information

Miramont Family Medicine

Miramont Family Medicine Miramont Family Medicine Adopted the Patient Centered Medical Home model to provide highest-quality, lowest-cost services to our patients Physician Owned Laboratory (POL) integral to delivery of our health

More information

The Advent of Subsequent Entry Biologics: Biosimilars Canada. The Advent of Subsequent Entry Biologics. Biosimilars in Canada

The Advent of Subsequent Entry Biologics: Biosimilars Canada. The Advent of Subsequent Entry Biologics. Biosimilars in Canada The Advent of Subsequent Entry Biologics: Biosimilars Canada The Advent of Subsequent Entry Biologics Biosimilars in Canada Spring 2014 Author: Patrick J. Mott, MSc. Editors Allison Hillier BA, MA Heather

More information

REFERENCE CODE GDHC1106CFR PUBLICATION DATE M AY 2013

REFERENCE CODE GDHC1106CFR PUBLICATION DATE M AY 2013 REFERENCE CODE GDHC1106CFR PUBLICATION DATE M AY 2013 PSORIASIS - Psoriasis - US Drug Forecast and Market Analysis to Executive Summary Sales for Psoriasis in the US 2012 We estimate the 2012 PsO drug

More information

Global Medicines Use in 2020

Global Medicines Use in 2020 November 2015 Global Medicines Use in 2020 Outlook and Implications Introduction The unprecedented expansion of access to healthcare globally over the past ten years ranging from hundreds of millions of

More information

Professor Ahmed H Al-jedai, PharmD, MBA, BCPS, FCCP, FAST, Saudi Arabia

Professor Ahmed H Al-jedai, PharmD, MBA, BCPS, FCCP, FAST, Saudi Arabia GaBI Scientific Meetings First GCC Stakeholder Meeting on Approval Process, Interchangeability/Substitution and Safety of Biosimilars 20 November 2017, Holiday Inn Izdihar Riyadh, Saudi Arabia Professor

More information

EMPLOYER BEST PRACTICES IN TELEHEALTH

EMPLOYER BEST PRACTICES IN TELEHEALTH EMPLOYER BEST PRACTICES IN TELEHEALTH Overview The rapid adoption of telehealth that started in 2010 has been driven not by healthcare providers, but instead by employers, seeking to address two of healthcare's

More information

Identifying population risk in new members requires aggregated health status data

Identifying population risk in new members requires aggregated health status data Identifying population risk in new members requires aggregated health status data Expert presenters Gus Gardner, Group President, Life Sciences, Optum As new enrollees flood in from growing public exchanges

More information

Pharma R&D and Patents support Health Care & Economy

Pharma R&D and Patents support Health Care & Economy Pharma R&D and Patents support Health Care & Economy Konstantinos Μ. Frouzis President of SFEE, V.P & Gen. Manager of Novartis Hellas April 28 th, 2014 Intellectual Property Patents: The vehicle for innovation

More information

Medicare Drug Discount Cards: A Work in Progress

Medicare Drug Discount Cards: A Work in Progress Medicare Drug Discount Cards: A Work in Progress Prepared for the Kaiser Family Foundation by Health Policy Alternatives, Inc. July 28, 2004 Study Objectives Assess Discount Card and TA programs mainly

More information

A High-Touch Approach to Improving Patient Access. Using field support to navigate reimbursement challenges

A High-Touch Approach to Improving Patient Access. Using field support to navigate reimbursement challenges A High-Touch Approach to Improving Patient Access Using field support to navigate reimbursement challenges For the brand and reimbursement teams who must develop commercial strategies for the biopharmaceutical

More information

Workshop on Access to and Uptake of Biosimilar Medicinal Products

Workshop on Access to and Uptake of Biosimilar Medicinal Products EUROPEAN COMMISSION Directorate-General for Internal Market, Industry, Entrepreneurship and SMEs Consumer, Environmental and Health Technologies Biotechnology and Food Supply Chain Workshop on Access to

More information

Sovaldi Pegasys Ribavirin

Sovaldi Pegasys Ribavirin Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.25 Subject: Sovaldi Pegasys Ribavirin Page: 1 of 6 Last Review Date: March 18, 2016 Sovaldi Pegasys

More information

Pharmamarketing - strategic challenges

Pharmamarketing - strategic challenges Pharmamarketing - strategic challenges Biomedicine Master Program Lund University Course: Biomedicine the Profession Anna Chérouvrier Hansson, MSc. December 16th, 2014 1. Pharmamarketing - definitions

More information

Pharmacogenomics and Health Policy

Pharmacogenomics and Health Policy Pharmacogenomics and Health Policy Amalia M. Issa, PhD, MPH Founding Director, Program in Personalized Medicine & Targeted Therapeutics Professor and Chair Department of Health Policy and Public Health

More information

Cindy Kehr Director of Purchasing & Pharmacy Services Keystone Rural Health Center

Cindy Kehr Director of Purchasing & Pharmacy Services Keystone Rural Health Center Cindy Kehr Director of Purchasing & Pharmacy Services Keystone Rural Health Center Statement of Conflicts of Interest Cindy Kehr has no actual or potential conflict of interest in relation to this presentation.

More information

The Value of Agile Self-Service Analytics. Mike Zuschin Director, Decision Support & Business Intelligence March 3 rd 2016

The Value of Agile Self-Service Analytics. Mike Zuschin Director, Decision Support & Business Intelligence March 3 rd 2016 The Value of Agile Self-Service Analytics Mike Zuschin Director, Decision Support & Business Intelligence March 3 rd 2016 Agenda Cleveland Clinic & Early Analytics Success: The Phantom Menace Meeting Increased

More information

Communicating Emerging Drug Therapies Prior to FDA Approval. May 4, 2017

Communicating Emerging Drug Therapies Prior to FDA Approval. May 4, 2017 Communicating Emerging Drug Therapies Prior to FDA Approval May 4, 2017 Michelle Drozd Deputy Vice President, Policy and Research Pharmaceutical Research Manufacturers Association (PhRMA) Michael Labson

More information

EHR AND ERP INTEGRATION. January 25, 2018

EHR AND ERP INTEGRATION. January 25, 2018 EHR AND ERP INTEGRATION January 25, 2018 Your Instructor Agenda Introduction to EHR and ERP EHR and ERP integration opportunities Evaluating the potential impact of EHR and ERP integration to your organization

More information

Striking a Healthy Balance. What Employees Really Want Out Of Workplace Benefits Communication

Striking a Healthy Balance. What Employees Really Want Out Of Workplace Benefits Communication Striking a Healthy Balance What Employees Really Want Out Of Workplace Benefits Communication Striking a Healthy Balance What Employees Really Want Out Of Workplace Benefits Communication Digital technology

More information

Goldman Sachs Health Care Conference

Goldman Sachs Health Care Conference Goldman Sachs Health Care Conference Laguna Niguel, California June 14, 2006 George Morrow Executive Vice President Global Commercial Operations Safe Harbor Statement This presentation contains forward-looking

More information

Decoding Phase II Clinical Trial Terminations

Decoding Phase II Clinical Trial Terminations Decoding Phase II Clinical Trial Terminations Why Phase II trials are terminated and what can be done to improve Phase II success rates - the most critical inflection point for clinical development Subha

More information

Misleading Congress about Drug Development: Reply

Misleading Congress about Drug Development: Reply Commentary Misleading Congress about Drug Development: Reply Joseph A. DiMasi Tufts University Ronald W. Hansen University of Rochester Henry G. Grabowski Duke University Abstract The review essay by Donald

More information

The U.S. Food and Drug Administration (FDA) is expected

The U.S. Food and Drug Administration (FDA) is expected Perspective C O R P O R A T I O N Expert insights on a timely policy issue The Cost Savings Potential of Biosimilar Drugs in the United States Andrew W. Mulcahy, Zachary Predmore, and Soeren Mattke The

More information

FDA Guidance, Clinical Pharmacology, and Regulatory Science

FDA Guidance, Clinical Pharmacology, and Regulatory Science Principles of Clinical Pharmacology NIH, April 25, 2013 FDA Guidance, Clinical Pharmacology, and Regulatory Science Carl Peck, MD UCSF Center for Drug Development Science Washington DC and San Francisco

More information

CDER 2016 Actions and 2017 Priorities. Richard Moscicki Deputy Center Director for Science Operations, CDER, FDA

CDER 2016 Actions and 2017 Priorities. Richard Moscicki Deputy Center Director for Science Operations, CDER, FDA CDER 2016 Actions and 2017 Priorities Richard Moscicki Deputy Center Director for Science Operations, CDER, FDA Disclosure My comments today are mine and do not necessarily represent the views of the US

More information

Second Quarter 2017 Earnings Teleconference. August 1, 2017

Second Quarter 2017 Earnings Teleconference. August 1, 2017 Second Quarter 2017 Earnings Teleconference August 1, 2017 Introduction Chuck Triano Senior Vice President, Investor Relations Forward-Looking Statements and Non-GAAP Financial Information 3 Our discussions

More information

STATE OF THE ASIA-PACIFIC PHARMACEUTICAL INDUSTRY 2013: EXECUTIVE SUMMARY

STATE OF THE ASIA-PACIFIC PHARMACEUTICAL INDUSTRY 2013: EXECUTIVE SUMMARY STATE OF THE ASIA-PACIFIC PHARMACEUTICAL INDUSTRY 2013: EXECUTIVE SUMMARY State of the Asia-Pacific Pharmaceutical Industry The pharmaceutical industry in the Asia-Pacific region has recently been besieged

More information

2016 Think Tank Barcelona

2016 Think Tank Barcelona 2016 Think Tank Barcelona Councilor Meeting Chris Griffiths Agenda 8:30 9am Big Data Symposium Follow-up Chris/Joelle 9 9:30 am Working Group Reports o Biosimilars Working Group Arnon o Topical Therapies

More information

INTERNATIONAL DIFFERENCES IN DRUG PRICES

INTERNATIONAL DIFFERENCES IN DRUG PRICES Annu. Rev. Public Health 2004. 25:475 95 doi: 10.1146/annurev.publhealth.25.101802.123042 Copyright c 2004 by Annual Reviews. All rights reserved INTERNATIONAL DIFFERENCES IN DRUG PRICES Judith L. Wagner

More information

Two Definitions of Market

Two Definitions of Market Marketing Niches Authors: Michael T. Rupp, PhD, RPh Professor of Pharmacy Administration Midwestern University Glendale Sondra J. Peters, MBA Assistant Professor of Pharmacy Administration Midwestern University

More information

FREQUENTLY ASKED QUESTIONS

FREQUENTLY ASKED QUESTIONS FREQUENTLY ASKED QUESTIONS Preferred Home Delivery Program for Maintenance Medications 1. What are maintenance medications? Maintenance medications are prescription drugs that you need to take regularly.

More information

How Logistics Enables the Healthcare Revolution. Richard Holmes Managing Director of Polar Speed Distribution Ltd, a UPS company

How Logistics Enables the Healthcare Revolution. Richard Holmes Managing Director of Polar Speed Distribution Ltd, a UPS company How Logistics Enables the Healthcare Revolution Richard Holmes Managing Director of Polar Speed Distribution Ltd, a UPS company Introduction There is a revolution taking place in healthcare delivery. Patient-centred

More information

ASHP Guidelines on Medication Cost Management Strategies for Hospitals and Health Systems

ASHP Guidelines on Medication Cost Management Strategies for Hospitals and Health Systems 458 Pharmacy Management Guidelines ASHP Guidelines on Medication Cost Management Strategies for Hospitals and Health Systems Because medication costs comprise the majority of healthsystem pharmacy budgets

More information

The Pharmaceutical Industry

The Pharmaceutical Industry The Pharmaceutical Industry by David Belk MD And Paul Belk PhD In previous sections of this website I ve written about the bizarre, two-level pricing system for prescription medications. Most generic medications

More information

Innovative Employer Benefits Strategies and the Business Value of Health

Innovative Employer Benefits Strategies and the Business Value of Health Innovative Employer Benefits Strategies and the Business Value of Health Bruce Sherman, MD, FCCP, FACOEM Medical Director, Employers Health Coalition October 10, 2013 Presentation content Business value

More information

STATEMENT SANDRA KWEDER, M.D DEPUTY DIRECTOR, OFFICE OF NEW DRUGS CENTER FOR DRUG EVALUATION AND RESEARCH U.S. FOOD AND DRUG ADMINISTRATION BEFORE THE

STATEMENT SANDRA KWEDER, M.D DEPUTY DIRECTOR, OFFICE OF NEW DRUGS CENTER FOR DRUG EVALUATION AND RESEARCH U.S. FOOD AND DRUG ADMINISTRATION BEFORE THE DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Rockville MD 20857 STATEMENT OF SANDRA KWEDER, M.D DEPUTY DIRECTOR, OFFICE OF NEW DRUGS CENTER FOR DRUG EVALUATION

More information

Executive Summary PBM Purchasers Guide A Quality Management Toolkit

Executive Summary PBM Purchasers Guide A Quality Management Toolkit Pharmacy Benefit Management PBM Purchasers Guide A Quality Management Toolkit Evaluating and Managing PBM Services in p a r t n e r s h i p w i t h e m p o w e r i n g c o n s u m e r s b y p r o m o t

More information

Texas Vendor Drug Program Fee-For-Service Medicaid Synagis Authorization Request

Texas Vendor Drug Program Fee-For-Service Medicaid Synagis Authorization Request Form 1033 September 2017-E Texas Vendor Drug Program Fee-For-Service Medicaid Synagis Authorization Request About Human Respiratory Syncytial Virus (RSV) causes respiratory tract infections and serious

More information

Commercial Pricing and Contracting 101

Commercial Pricing and Contracting 101 Commercial Pricing and Contracting 101 Reimbursement and Contracting CBI Conference Philadelphia, PA February 4, 2016 Althea Danzey, Director of Contracting Tina Still, Senior Manager of Contracting Eisai

More information

The Emerging Technology Program: FDA s Perspective

The Emerging Technology Program: FDA s Perspective The Emerging Technology Program: FDA s Perspective Mohan Sapru, M.S., Ph.D. Member Emerging Technology Team (ETT) CMC Lead Application Technical Lead Office of New Drug Products Office of Pharmaceutical

More information

The NBCH PBM Assessment. A Cross-PBM RFI

The NBCH PBM Assessment. A Cross-PBM RFI The NBCH PBM Assessment A Cross-PBM RFI Why an External PBM Assessment? Coalition Interest Over Half of NBCH Coalitions responding to Survey: 80% said their members asked about such information PBM Interest

More information

Partnering & Networks

Partnering & Networks Partnering & Networks Success drivers in an ever changing and complex health care system Dr. Benedikt Hoffmann, Senior Manger New Business Development & J&J Innovation Manager October 2 nd, 2014 Judith

More information

Insights into the Evolving Pricing & Market Access Environment

Insights into the Evolving Pricing & Market Access Environment Insights into the Evolving Pricing & Market Access Environment UBC Global Market Access Survey July 2012 JULY 2012 GLOBAL MARKET ACCESS SURVEY UBC s Global Market Access Survey: Setting the Stage For those

More information

REFERENCE CODE GDHC218CFR PUBLICAT ION DATE FEBRUARY 2014 ULCERATIVE COLITIS - US DRUG FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC218CFR PUBLICAT ION DATE FEBRUARY 2014 ULCERATIVE COLITIS - US DRUG FORECAST AND MARKET ANALYSIS TO 2022 REFERENCE CODE GDHC218CFR PUBLICAT ION DATE FEBRUARY 2014 ULCERATIVE COLITIS - US DRUG FORECAST AND MARKET ANALYSIS TO 2022 Executive Summary Sales for Ulcerative Colitis in the United States In 2012,

More information

leading the way in research & development

leading the way in research & development leading the way in research & development people. passion. possibilities. ABBVIE 2 immunology AbbVie Immunology has a demonstrated record of success in identifying and developing both small molecule and

More information

New WHO Report: Access to new medicines in Europe: Technical review of policy initiatives and opportunities for collaboration and research

New WHO Report: Access to new medicines in Europe: Technical review of policy initiatives and opportunities for collaboration and research New WHO Report: Access to new medicines in Europe: Technical review of policy initiatives and opportunities for collaboration and research Hanne Bak Pedersen Programme Manager Health Technologies and Pharmaceuticals

More information

Indian CRAMS players to cram in growth: CARE Ratings

Indian CRAMS players to cram in growth: CARE Ratings January, 2015 Credit Perspective : Indian CRAMS Indian CRAMS players to cram in growth: CARE Ratings CARE Ratings expects Indian Contract Research and Manufacturing Services (CRAMS) players to register

More information

CLINICAL TRIAL ENROLLMENT FORECASTING A WEB-BASED PERFORMANCE MANAGEMENT APPLICATION

CLINICAL TRIAL ENROLLMENT FORECASTING A WEB-BASED PERFORMANCE MANAGEMENT APPLICATION CLINICAL TRIAL ENROLLMENT FORECASTING A WEB-BASED PERFORMANCE MANAGEMENT APPLICATION BUSINESS VALUE GUIDE CLINICAL TRIAL ENROLLMENT FORECASTING CHALLENGES Patient enrollment is a major headache for life

More information

AN IHS ECONOMICS REPORT The Benefits of Chlorine Chemistry in Pharmaceuticals in the United States and Canada

AN IHS ECONOMICS REPORT The Benefits of Chlorine Chemistry in Pharmaceuticals in the United States and Canada AN IHS ECONOMICS REPORT The Benefits of Chlorine Chemistry in Pharmaceuticals in the United States and Canada September 2016 PREPARED FOR THE AMERICAN CHEMISTRY COUNCIL Ron Whitfield Vice President, Applied

More information

Customer Service in a Multi-Channel World 2. Table of Contents

Customer Service in a Multi-Channel World 2. Table of Contents Customer Service in a Multi-Channel World How to Profit from the Shift to Multi-Channel Customer Service August 2008 Customer Service in a Multi-Channel World 2 Table of Contents Executive Summary 3 It

More information

FDA Just Approved Some Highly Anticipated Specialty Drugs; Payers Must Prepare Now

FDA Just Approved Some Highly Anticipated Specialty Drugs; Payers Must Prepare Now FDA Just Approved Some Highly Anticipated Specialty Drugs; Payers Must Prepare Now By Angela Maas, Managing Editor April 2017Volume 14Issue 4 In late March, the FDA went on an approval tear, paving the

More information

Future of Pharmaceutical Quality and the Path to Get There

Future of Pharmaceutical Quality and the Path to Get There Future of Pharmaceutical Quality and the Path to Get There Lawrence Yu, Ph.D. Deputy Director, Office of Pharmaceutical Quality FDA Center for Drug Evaluation and Research 3rd PQRI/FDA Conference on Advancing

More information

Session 9 Building an Enterprise Analytics Organization. Joseph M. Dudas Division Chair, Enterprise Analytics Mayo Clinic

Session 9 Building an Enterprise Analytics Organization. Joseph M. Dudas Division Chair, Enterprise Analytics Mayo Clinic Session 9 Building an Enterprise Analytics Organization Joseph M. Dudas Division Chair, Enterprise Analytics Mayo Clinic Learning Objectives Understand the phases of building an enterprise-wide analytics

More information